Genetically-driven traditional Chinese medicine target prediction and evaluation method and system
By integrating molecular biology and traditional Chinese medicine methods, using genome-wide association data and protein interaction networks, we can identify key targets of chronic diseases and build traditional Chinese medicine-related databases, which solves the problem of predicting targets for chronic diseases and improves the therapeutic effect and quality of life.
Patent Information
- Application Number
- CN202410720498.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-05
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively predict and treat chronic complex diseases such as autoimmune thyroid disease, especially lacking effective genetically driven targets and therapeutic means.
Using a genetically driven Chinese medicine target prediction and evaluation method, the gene-prediction is constructed by integrating molecular biology, traditional Chinese medicine and bioinformatics, using genome-wide association data, multimodal regulatory genome data and protein interaction networks. Factor matrix, identify priority genes, and identify key targets through pathway intersection network analysis, thereby building a network of databases related to traditional Chinese medicine, and recommending traditional Chinese medicine compound prescriptions and compounds.
It has achieved accurate prediction of potential targets for chronic complex diseases, provided new Chinese medicine treatment ideas, improved the effectiveness and quality of life of disease treatment, and promoted the progress of research on integrated traditional Chinese and Western medicine.
Smart Images

Figure CN118969061A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of Chinese medicine target prediction, and in particular to a genetically driven Chinese medicine target prediction and evaluation method and system. Background Art
[0002] Chronic diseases, such as chronic respiratory diseases, cancer, autoimmune diseases, metabolic diseases, cardiovascular diseases, neurodegenerative diseases, etc., are complex diseases with long course, high incidence, spread and incurable, requiring long-term medication or rehabilitation treatment. Therefore, the prevention and treatment of chronic diseases has become a top priority for national health.
[0003] Traditional Chinese medicine is a treasure that has been passed down for thousands of years in my country. It can be applied to the prevention, diagnosis, and treatment of chronic diseases. It conducts "disease dialectics" through observation, auscultation, questioning, and palpation, and analyzes the results to "discuss treatment". According to the "symptoms", "Chinese herbal compound" is selected for treatment. The prevention and treatment of traditional Chinese medicine emphasizes the concept of "prevention before illness, prevention of changes after illness, and prevention of recurrence after illness". It is an empirically verified effective means of preventing and treating chronic diseases, which helps to soothe and balance the body's various physiological functions and metabolic levels, delay or prevent the occurrence of diseases, and greatly improve the health status and quality of life of patients. Modern Chinese medicine treatment is essentially different from Western medicine treatment. Chinese medicine treatment focuses on overall syndrome differentiation and treatment, emphasizes the analysis and treatment of etiology, and uses a variety of means to treat diseases, such as acupuncture, decoctions, Chinese medicine, massage, etc., which are often used in various stages of treatment, rehabilitation, and prevention of diseases. In addition, because Chinese medicine emphasizes physical management and self-conditioning, it can be used to prevent diseases.
[0004] Take autoimmune thyroid disease (AITD), which is currently the most common autoimmune disease, as an example. It is a common thyroid-specific autoimmune disease, which is mainly caused by the combined influence of genetic and environmental factors and can cause systemic multi-organ dysfunction. In recent years, the incidence of the disease has increased year by year. At present, the pathogenesis of AITD is still unclear, and there is a lack of effective treatment. AITD can cause abnormal thyroid function, manifested as hyperthyroidism (Hyperthyroidism, referred to as "hyperthyroidism") and hypothyroidism (Hypothyroidism, referred to as "hypothyroidism"). In modern Chinese medicine, thyroid diseases are classified as "goiter" and "deficiency". TCM treatment focuses on overall syndrome differentiation and treatment, taking into account the patient's constitution and organ function, so as to achieve refined prevention and treatment of AITD. Chinese medicine compound treats the disease through different combinations of Chinese medicines. This "multi-component-multi-target-multi-pathway" treatment method also enables Chinese medicine to play an important clinical efficacy. The study found that TCM can regulate the inflammatory response and immune function of AITD patients, reduce oxidative stress, and inhibit cell apoptosis by acting on targets and affecting biological pathway networks, thereby alleviating the clinical symptoms of AITD patients, delaying the progression of the disease, and significantly improving the quality of life of patients. This further verifies the potential and value of TCM in the treatment of AITD.
[0005] Complex disease research focusing on omics big data helps identify disease treatment targets, while drug targets supported by genetic evidence can increase the rate of drug development. Therefore, target selection driven by omics genetic evidence is the focus of innovative drug development. Researcher Fang Hai from the National Center for Translational Medicine (Shanghai), Ruijin Hospital, Shanghai Jiao Tong University, has accumulated a solid research foundation in the new paradigm of computational medicine research represented by "genetic evidence supports target discovery", and has promoted this new research paradigm to the study of a variety of complex diseases. So far, it has successfully supported third-party users to carry out genetic target discovery work many times, including but not limited to immune system diseases, asthma, pancreatic cancer, type I diabetes, Alzheimer's disease, etc., which has greatly promoted the research progress in the field of genetic target computational medicine. Therefore, drawing on this idea, using whole genome association data to identify potential genetic therapeutic targets for chronic complex diseases is expected to provide new ideas for the treatment of chronic complex diseases. Summary of the invention
[0006] In view of the above problems, the purpose of the present invention is to provide a genetically driven method and system for predicting and evaluating targets of traditional Chinese medicine. By integrating molecular biology, traditional Chinese medicine, bioinformatics and other disciplines, a new strategy for the study of integrated Chinese and Western medicine is proposed: a genetically driven method for predicting and evaluating targets of traditional Chinese medicine. By using the key core algorithm of computational medicine, the "priority index", potential targets are discovered at the molecular biology level, and traditional Chinese medicine is associated with them, thereby obtaining recommended traditional Chinese medicine treatment compounds, in order to provide a reference for preclinical research and clinical prevention and treatment of chronic complex diseases. The research strategy proposed in this article opens up new ideas for the study of traditional Chinese and Western medicine, and also provides new insights for subsequent clinical treatment of traditional Chinese medicine.
[0007] The above-mentioned object of the present invention is achieved through the following technical solutions:
[0008] A genetically driven method for predicting and evaluating traditional Chinese medicine targets comprises the following steps:
[0009] S1: Obtain the significant associated SNP sites of the chronic complex diseases to be predicted as genome-wide association study data, identify the key genes and key associated genes regulated by the significant associated SNP sites, construct a gene-predictor matrix based on the significant associated SNP sites, the key genes and the key associated genes, identify priority genes based on the gene-predictor matrix, construct a pathway intersection network analysis based on the priority genes to identify key targets, and identify drug repurposing evidence based on the pathway intersection network;
[0010] S2: Based on the key targets and the drug reuse evidence, a TCMnet database network related to traditional Chinese medicine is constructed, and based on the key targets, predictions are made on traditional Chinese medicine compound prescriptions, traditional Chinese medicine compounds, disease treatment plans and disease health care plans.
[0011] Further, in step S1, the key gene regulated by the significant associated SNP site and the key associated gene are identified, specifically:
[0012] In order to identify the key gene regulated by the significant associated SNP site of the genetic locus to be predicted for the chronic complex disease, multimodal regulatory genomics data is used to define, including at least one of the following:
[0013] A: Neighbor factor associated with the significant associated SNP site;
[0014] B: defining genetic regulatory factors according to the expression quantitative trait loci eQTL or protein quantitative trait loci pQTL associated with the chronic complex disease to be predicted;
[0015] C: Definition of long-range interacting factors based on promoter capture Hi-C data;
[0016] Taking the key gene as the initial starting point, by integrating the protein interaction network data, the random walk algorithm RWR with restart is used to calculate the degree of connection between the protein interaction network data and the key gene, and then identify the key associated gene of the key gene, specifically:
[0017] Referring to Formula 1, starting with the key gene as a node, there are two choices at each walk: either move to a randomly selected neighboring node, or jump back to the starting point, and iterate repeatedly until all nodes are traversed. Referring to Formula 2, the probability vector obtained at this time contains all nodes, that is, the affinity scores of all key associated genes with the key gene as the initial starting point, ranging from 0 to 1;
[0018]
[0019]
[0020] Wherein, γ represents the restart probability of jumping back to the seed node, the seed node is the initial starting point, 1-γ represents the probability of moving to the neighboring node, A represents the standardized Laplacian adjacency matrix related to the network data, represents the starting probability vector containing the seed gene scores, which is 0 for non-seed genes. represents the probability vector of the stable state of the algorithm when visiting the network node for the tth time, The probability vector representing the stable state of the algorithm visiting the network node for the t-1th time, after reaching stability, assigning the affinity scores of all nodes in the network to the seed node.
[0021] Further, in step S1, the gene-prediction factor matrix is constructed based on the significant associated SNP sites, the key genes and the key associated genes, specifically:
[0022] The neighbor factor, the genetic regulatory factor and the long-range interaction factor are used as predictors, the neighbor factor is used as a baseline predictor, and a subset having the same weight as the neighbor factor is obtained from the genetic regulatory factor and the long-range interaction factor;
[0023] Mapping all the predictors to genes, constructing the gene-predictor matrix, wherein the X-axis represents the gene, the Y-axis represents the predictor, and each element in the gene-predictor matrix represents the strength of association between a gene and a predictor;
[0024] Considering genes and the predictors as nodes in a graph, and considering the associations between genes and the predictors as edges, a network graph is constructed;
[0025] A random walk algorithm is used to walk on the constructed network graph to calculate the weight of each prediction factor. After removing a certain prediction factor, the walk is performed again to measure the change in the weight of the prediction factor. If the accuracy drops significantly after removing a certain prediction factor, the prediction factor is considered to be valuable and is retained.
[0026] Further, in step S1, the priority genes are identified based on the gene-prediction factor matrix, specifically:
[0027] Prioritization prediction is performed using a logistic scheme similar to a meta-analysis method, and predictor variables are merged according to the constructed gene-predictor matrix, in which the affinity score of the predictor given by formula 3 is converted into a P-value by an empirical cumulative density function eCDF, and the empirical cumulative density function eCDF is estimated by the affinity scores of all genes on the predictor;
[0028]
[0029] in, represents the affinity score of the ith gene on the jth predictor, represents the P value of the i-th gene after conversion on the j-th predictor;
[0030] Subsequently, referring to formulas 4-6, the transformed P values of different predictors are combined by the Logistic scheme, and the final combined P value is readjusted to produce a priority level from 0 to 10, and the output result is the priority ranking method of the priority ranking genes, referring to formula 7;
[0031]
[0032] x i ~x 2 (2J), (5)
[0033] CP i =CDF(x i ), (6)
[0034]
[0035] in, represents the P value of the i-th gene after transformation on the j-th predictor, where J is the number of predictors, and x i represents the combined statistic of the ith gene, χ 2(2J) represents the combined statistic X with 2J degrees of freedom 2 The distribution of CP i represents the combined P value of the ith gene, i.e., the eCDF of the chi-square distribution at x i The value of CS i represents the finite fraction of the i-th gene, a total of K genes, CP k represents the combined P value of the kth gene.
[0036] Further, in step S1, a pathway intersection network analysis is constructed based on the prioritized genes to identify key targets, specifically:
[0037] The top-ranked priority genes are selected, and a high-priority and highly correlated gene subset is identified in the KEGG network using a heuristic Stein tree search algorithm. It is also necessary to ensure that the interaction relationship between each gene or the edge in the KEGG network exists in at least one pathway. The gene subnetwork composed of the identified gene subset is the pathway intersection network. In order to evaluate the significance of the pathway intersection network, a 100-iteration degree-preserving node permutation test is selected for evaluation. The key targets finally outputted are all the nodes gathered on the pathway intersection network after iterative search.
[0038] Further, in step S1, drug repurposing evidence is identified based on the pathway intersection network, specifically:
[0039] Drug repurposing analysis relies on information extracted from the bioactive compound database ChEMBL, which summarizes therapeutic data including drugs, development stages, target genes, and disease indications for current phase II and approved therapies;
[0040] For the chronic complex disease to be predicted, considering that the key target gene has a clear mechanism of action and can explain the efficacy of the drug in treating the disease, the drug that has reached the maximum stage of development will be selected by the key target gene;
[0041] The genes of these selected key targets were divided into two different groups: one group included approved drug targets and the other group included drug targets under development, and the one-sided Fisher's exact test was used to assess the statistical significance of the enrichment of the two groups of drug targets into pathway intersection genes.
[0042] Further, in step S2, based on the key targets and the drug reuse evidence, a TCMnet database network is constructed, specifically:
[0043] Retrieve information from TCM-related databases, including the TCMSP database and analysis platform for TCM systems pharmacology, SymMap database for TCM syndrome association, and BATMAN-TCM2.0 database for TCM pharmacology, and manually organize the information, focusing on the relationship between drugs, targets, diseases, and symptoms;
[0044] Based on the TCM-related database information, the information on Chinese herbal medicine types, Chinese herbal medicine ingredients, Chinese herbal medicine compounds, TCM symptoms, modern medical symptoms, disease information, and gene target points are sorted out and finally summarized into the TCM-related database network TCMnet associated with drugs, targets, diseases, and symptoms. The relevant data is stored in the form of a MySQL database. The TCM-related database network supports searching for Chinese herbal medicine ingredients by gene targets, or searching for gene targets based on Chinese herbal medicine ingredients, or searching for gene targets and Chinese herbal medicine ingredients by diseases.
[0045] Further, in step S2, the Chinese medicine compound is predicted based on the key targets, specifically:
[0046] Based on the genes of the key targets identified by the pathway intersection network, the Chinese medicine-related database network is used to retrieve the Chinese herbal medicine types related to the genes of the key targets, and the frequency statistical analysis of the Chinese herbal medicine types included in the group is performed, and the Chinese herbal medicine components that appear more than half of the times in the genes of the key targets are selected as the recommended Chinese medicine treatment compound;
[0047] In order to ensure the effectiveness of the recommended TCM compound, the core formulas for diseases currently published were searched in the literature for further comparison, and finally the TCM compound for complex diseases was determined.
[0048] Further, in step S2, the Chinese medicine compound is predicted based on the key target, specifically:
[0049] Based on the genes of the key targets identified by the pathway intersection network, the Chinese medicine-related database network is used to retrieve the Chinese herbal compounds related to the genes of the key targets, and the included Chinese herbal compound components are searched, and the Chinese herbal compound components that appear more than half of the times in the genes of the key targets are selected. At the same time, the corresponding additional information annotations are retrieved, and the corresponding combination is selected for subsequent research based on the top-ranked Chinese herbal compound component table.
[0050] Furthermore, in step S2, a disease treatment plan is predicted based on the key targets, specifically:
[0051] Based on the genes of the key targets identified by the pathway intersection network, the corresponding disease type is selected, and the Chinese herbal medicine types and compounds related to the genes of the key targets are retrieved using the Chinese medicine-related database network. The pathway intersection network analysis is constructed for the Chinese herbal medicine types and compound components included in the group to identify the key Chinese herbal medicine types and compound components. At the same time, relevant Chinese herbal medicine types can be added by customization, and finally candidate disease treatment plans are output.
[0052] Furthermore, in step S2, the disease health care plan is predicted based on the key targets, specifically:
[0053] Based on the genes of the key targets identified by the pathway intersection network, the relevant disease types are selected, and the Chinese herbal medicine types and compounds related to the genes of the key targets are retrieved using the Chinese medicine-related database network. The pathway intersection network analysis is constructed for the Chinese herbal medicine types and compound components included in the group to identify the key Chinese herbal medicine types and compound components. At the same time, relevant Chinese herbal medicine types can be added by customization, and finally the disease health care plan that can be recommended by the present invention is output.
[0054] The present invention can also provide users with a multi-faceted consultation system, which is convenient for users to more intuitively understand the disease type corresponding to the symptoms and how to select symptom information, so that users can more accurately screen out corresponding disease treatment plans and disease health care plans.
[0055] A genetically driven Chinese medicine target prediction and evaluation system for executing the above-mentioned genetically driven Chinese medicine target prediction and evaluation method comprises:
[0056] A key gene prediction module is used to obtain the significant associated SNP sites of the chronic complex disease to be predicted as genome-wide association study data, identify the key genes and key associated genes regulated by the significant associated SNP sites, construct a gene-prediction factor matrix based on the significant associated SNP sites, the key genes and the key associated genes, identify priority genes based on the gene-prediction factor matrix, construct a pathway intersection network analysis based on the priority genes to identify key targets, and identify drug repurposing evidence based on the pathway intersection network;
[0057] The drug target prediction module is used to construct a traditional Chinese medicine related database network TCMnet based on the key targets and the drug reuse evidence, and to predict traditional Chinese medicine compound prescriptions, traditional Chinese medicine compounds, disease treatment plans and disease health care plans based on the key targets.
[0058] The multidisciplinary integration and innovation of molecular biology, traditional Chinese medicine, and bioinformatics is one of the most effective means of basic research, which is of great significance to modern Chinese medicine research. However, the current research methods and strategies are still only in the initial exploration stage, and researchers need to further think boldly, actively innovate, and explore tirelessly. Therefore, this new research strategy of combining traditional Chinese and Western medicine proposed in the present invention can provide new ideas for subsequent Chinese medicine research, and the specific technical advantages are as follows:
[0059] (1) The present invention integrates data such as multimodal regulatory genomic datasets (genetic evidence), protein interaction information (network evidence), and comprehensively compares the ranking performance of multiple methods such as Logistic, Fisher's, order statistic, sum, and max. Finally, the gene prediction matrix of affinity scores is generated using Logistic combination of various predictors, and the genetic loci of chronic diseases are associated with candidate target genes. The present invention is driven only by genetics, integrates network interactions, and performs unsupervised prediction of therapeutic targets. The identified priority genes may serve as potential drug targets.
[0060] (2) Another highlight of the present invention is that it proposes a network disturbance removal analysis based on pathway intersection networks, which locates the quantitatively recommended targets in a sub-network with higher credibility, and then analyzes the interference of each node in the sub-network to the sub-network, so as to finally determine the candidate intervention targets.
[0061] (3) The third highlight of the present invention is to associate genomic data with traditional Chinese medicine data, convert gene-level targets into information related to traditional Chinese medicine ingredients and traditional Chinese medicine targets, and then construct a "drug-target-disease-symptom" network for each traditional Chinese medicine ingredient, and finally identify potential traditional Chinese medicine targets and related traditional Chinese medicine compound information.
[0062] (4) The present invention can provide user-friendly open source R packages, online web pages and other functional products, and is accompanied by a detailed user manual that provides step-by-step instructions to facilitate users to use and browse the product, promoting integrated and efficient knowledge discovery. The present invention has open, repeatable and scalable functions, and is expected to be flexibly applied to drug target prediction in more cross-disciplinary fields.
[0063] With the above advantages, the present invention can provide researchers with a new idea for the integration of Chinese and Western medicine research, and is committed to finding potential therapeutic targets for complex diseases, providing guidance for disease treatment, and also providing new directions for subsequent Chinese medicine mechanism research and clinical research, in order to contribute to the development of disciplines in the field of traditional Chinese medicine. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1 The overall flow chart of the genetically driven traditional Chinese medicine target prediction and evaluation method of the present invention;
[0065] Figure 2 The overall structure diagram of the genetically driven traditional Chinese medicine target prediction and evaluation system of the present invention;
[0066] Figure 3 A schematic diagram of the principle of the genetically driven traditional Chinese medicine target prediction and evaluation method of the present invention;
[0067] Figure 4 Schematic diagram of the performance benchmark experiment of the priority ranking method of the present invention, wherein (a) is a comparison of the priority ranking methods, including meta-analysis schemes (Logistic, Fisher's, order statistic) and traditional schemes (sum, max); (b) is a comparison with existing methods, including and Open Targets Genetics methods to measure the performance of different schemes by the area under the ROC curve (AUC);
[0068] Figure 5 This is a schematic diagram of the quantitative recommendation of genes based on the priority ranking method of the present invention. (a) is a Manhattan diagram showing the priority ranking results of approximately 14,700 target genes according to genomic position (y-axis), and the top two priority genes on each chromosome are marked on the x-axis. (b) is a ranking diagram of the quantitative recommendation results of drug targets for autoimmune diseases at stage II or above. The top priority autoimmune thyroid disease clinical stage II or above drug targets (n=17) are represented by gene symbols and represented by vertical lines. The top-ranked priority genes are the core subset of target genes, representing the signal peak on the far left in the continuous enrichment map (middle figure). All top priority genes are called "lead target genes" (n=1169). (c) is a schematic diagram of clinical stage II or above drug targets corresponding to lead target genes;
[0069] Figure 6 Schematic diagram of the priority genes in hyperthyroidism and hypothyroidism of the present invention, the Manhattan plot shows the priority score (y-axis) of each target gene (x-axis), and the highest-ranked priority genes are shown on each chromosome;
[0070] Figure 7 Schematic diagram of molecular marker enrichment of hyperthyroidism and hypothyroidism of the present invention, circles represent features (upper panel), and the figure shows the enrichment of hyperthyroidism (lower left panel) and hypothyroidism (lower right panel) respectively;
[0071] Figure 8The schematic diagram of the pathway intersection network of hyperthyroidism and hypothyroidism of the present invention, (a) is the heat map of the pathway intersection genes of hyperthyroidism and hypothyroidism, and the intersection genes are divided into three groups: a shared group present in both autoimmune subtypes, a hyperthyroidism-specific group, and a hypothyroidism-specific group. (b) is the pathway intersection network of hyperthyroidism and hypothyroidism, each pathway is identified by combining target priority information with pathway-derived gene interactions (merged from KEGG pathways);
[0072] Fig. 9 Schematic diagram of drug repurposing analysis based on pathway intersection network of the present invention, (a) is an enrichment analysis forest diagram used to determine whether the key target genes identified in the pathway intersection network are enriched to drug targets that have been approved or are in the development stage (drug target information is derived from ChEMBL), (b) is a heat map showing all indication information corresponding to targets with clinical concept support;
[0073] Fig.10 This is a schematic diagram of the composition of the traditional Chinese medicine compound for identifying potential target genes for hyperthyroidism and hypothyroidism of the present invention, where * indicates the compound ingredients present in the core formula. DETAILED DESCRIPTION
[0074] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.
[0075] Those skilled in the art will appreciate that, unless otherwise stated, the singular forms "a", "an", "said" and "the" used herein may also include plural forms. It should be further understood that the term "comprising" used in the specification of the present invention refers to the presence of the features, integers, steps, operations, elements and / or components, but does not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components and / or groups thereof.
[0076] The present invention proposes a genetics-driven method for predicting and evaluating traditional Chinese medicine targets, which includes: prioritizing gene prediction based on genetic genomics data support and predicting drug targets based on traditional Chinese medicine data.
[0077] Prediction of priority genes based on genomics data: By integrating genome-wide association analysis data, regulatory genomics data (using multimodal regulatory genomics data sets such as QTL and PCHi-C), and molecular biology relationship network information (using protein interactions from the STRING database), the genetic findings of chronic complex diseases are converted into quantitatively recommended priority genes supported by genetic evidence, and the target genes are ranked from 0 to 10 based on the quantitative recommendation results. Subsequently, pathway intersection network analysis and network perturbation removal analysis are performed using the top-ranked quantitatively recommended genes and biomolecular relationship network information to identify potential targets for chronic disease treatment.
[0078] Drug target prediction based on TCM data: Based on the prediction of chronic disease treatment targets identified by prioritized genes supported by genomics data and TCM-related database information, gene-level targets are converted into information related to TCM ingredients and TCM targets. Subsequently, based on this information, a "drug-target-disease-symptom" network is constructed for each TCM ingredient, ultimately identifying potential TCM targets and related TCM compound information.
[0079] The following is described by specific examples:
[0080] First embodiment
[0081] like Figure 1 As shown, this embodiment provides a genetically driven method for predicting and evaluating traditional Chinese medicine targets, which is characterized by comprising the following steps:
[0082] S1: Obtain the significant associated SNP sites for the chronic complex diseases to be predicted as the whole genome association study data, identify the key genes and key associated genes regulated by the significant associated SNP sites, construct a gene-predictor matrix based on the significant associated SNP sites, the key genes and the key associated genes, identify priority genes based on the gene-predictor matrix, construct a pathway intersection network analysis based on the priority genes to identify key targets, and identify drug reuse evidence based on the pathway intersection network.
[0083] In this embodiment, step S1 is a process for predicting priority genes based on support from genomics data: by integrating genome-wide association analysis data, regulatory genomics data (using multimodal regulatory genomics data sets such as QTL and PCHi-C), and molecular biology relationship network information (using protein interactions from the STRING database), the genetic findings of chronic complex diseases are converted into quantitatively recommended priority genes supported by genetic evidence, and the target genes are ranked from 0 to 10 according to the quantitative recommendation results. Subsequently, pathway intersection network analysis and network perturbation removal analysis are performed using the top-ranked quantitatively recommended genes and biomolecular relationship network information to determine potential targets for chronic disease treatment. The following focuses on this part and describes the specific process:
[0084] (1) Organizing genome-wide association study data of chronic complex diseases
[0085] By searching the experimental factor ontology (EFO ontology) containing the keyword "disease to be studied" in the NHGRI-EBI GWAS Catalog database (https: / / www.ebi.ac.uk / gwas / ), all GWAS summary data related to the "disease to be studied" disease were downloaded. Subsequently, these data were filtered to select SNP sites with significant association (P-value < 5×10 -8 ) and use the data as input for subsequent data analysis.
[0086] (2) Identification of key genes and key associated genes
[0087] Identify the key gene regulated by the significant associated SNP site and the key associated gene, specifically:
[0088] In order to identify the key gene regulated by the significant associated SNP site of the genetic locus to be predicted for the chronic complex disease, multimodal regulatory genomics data is used to define, including at least one of the following:
[0089] A: Neighbor factor associated with the significant associated SNP site;
[0090] B: defining genetic regulatory factors according to the expression quantitative trait loci eQTL or protein quantitative trait loci pQTL associated with the chronic complex disease to be predicted;
[0091] C: Definition of long-range interacting factors based on promoter capture Hi-C data;
[0092] Furthermore, taking the key gene as the initial starting point, by integrating the protein interaction network data, the random walk algorithm RWR (random walk with restart) is used to calculate the degree of connection between the protein interaction network data and the key gene, and then the key associated gene of the key gene is identified, specifically:
[0093] Referring to Formula 1, starting with the key gene as a node, there are two choices at each walk: either move to a randomly selected neighboring node, or jump back to the starting point, and iterate repeatedly until all nodes are traversed. Referring to Formula 2, the probability vector obtained at this time contains all nodes, that is, the affinity scores of all key associated genes with the key gene as the initial starting point, ranging from 0 to 1;
[0094]
[0095]
[0096] Wherein, γ represents the restart probability of jumping back to the seed node, the seed node is the initial starting point, 1-γ represents the probability of moving to the neighboring node, A represents the standardized Laplacian adjacency matrix related to the network data, represents the starting probability vector containing the seed gene scores, which is 0 for non-seed genes. represents the probability vector of the stable state of the algorithm when visiting the network node for the tth time, The probability vector representing the stable state of the algorithm visiting the network node for the t-1th time, after reaching stability, assigning the affinity scores of all nodes in the network to the seed node.
[0097] For each of the different categories of genetic factors (i.e., neighbor factors, genetic regulatory factors, and long-range interaction factors), predictors of key genes and key associated genes are generated, along with affinity scores that quantify their network connectivity with key genes. Notably, genes with higher network connectivity with key genes are assigned higher affinity scores. In general, key genes are more likely to receive higher affinity scores than key associated genes. Nevertheless, a key associated gene may also receive a high affinity score if it has high connectivity with most (but not all) seed genes. Therefore, non-seed key associated genes with higher affinity scores represent genes that are more affected by the network.
[0098] (3) Constructing a gene-predictor matrix: Based on the significant SNP sites, key genes, and key associated genes identified in the previous steps, a random walk algorithm is used to construct a gene-predictor matrix, which is then used to evaluate the weights of the predictors, where the X-axis represents the gene and the Y-axis represents the predictor. In this step, the random walk algorithm is used to evaluate the weights of the predictors, mainly by measuring whether the removal of a certain predictor causes a significant decrease in accuracy, thereby ensuring that only valuable predictors are left. Here, the neighbor factor is generally used as the baseline predictor in the present invention, and a subset of genetic regulatory factors and long-range interaction factors with the same weight value as the neighbor factor is considered. Therefore, a gene-predictor matrix of about 15,000 genes will be obtained in the end, specifically:
[0099] The neighbor factor, the genetic regulatory factor and the long-range interaction factor are used as predictors, the neighbor factor is used as a baseline predictor, and a subset having the same weight as the neighbor factor is obtained from the genetic regulatory factor and the long-range interaction factor;
[0100] Mapping all the predictors to genes, constructing the gene-predictor matrix, wherein the X-axis represents the gene, the Y-axis represents the predictor, and each element in the gene-predictor matrix represents the strength of association between a gene and a predictor;
[0101] Considering genes and the predictors as nodes in a graph, and considering the associations between genes and the predictors as edges, a network graph is constructed;
[0102] A random walk algorithm is used to walk on the constructed network graph to calculate the weight of each predictor. After removing a predictor, the walk is performed again to measure the change in the weight of the predictor. If the accuracy drops significantly after removing a predictor, the predictor is considered to be valuable and is retained.
[0103] (4) Quantitative performance benchmarking of recommended gene prioritization
[0104] Based on the gene-predictor matrix constructed in the above steps, three performance benchmark comparison methods are selected in the present invention: i) similar meta-analysis methods: Logistic, Fisher's, order statistic combination method; ii) traditional analysis methods: sum (adding affinity scores between predictors) and max (selecting the maximum value among predictors); iii) existing drug target prediction methods: (genes are quantitatively ranked based on the frequency of being targeted by approved drugs, with data from the ChEMBL database) and Open Target Genetics (drug target identification method based on genomics big data, with data from the Cambridge University Open Target database).
[0105] (5) Prioritization method: Identify the priority genes based on the gene-prediction factor matrix, specifically:
[0106] The present invention uses a logistic scheme similar to the meta-analysis method to perform priority ranking prediction based on the results of the performance benchmark test in the previous step, and merges the prediction variables according to the constructed gene-predictor matrix. In the gene-predictor matrix, the affinity score of the predictor given by formula 3 is converted into a class P value by an empirical cumulative density function eCDF, and the empirical cumulative density function eCDF is estimated by the affinity scores of all genes on the predictor;
[0107]
[0108] in, represents the affinity score of the ith gene on the jth predictor, represents the P value of the i-th gene after conversion on the j-th predictor;
[0109] Subsequently, referring to formulas 4-6, the transformed P values of different predictors are combined by the Logistic scheme, and the final combined P value is readjusted to produce priority levels from 0 to 10, corresponding to priority times from 1 to 15000, and the output result is the priority ranking method of the priority ranking genes, referring to formula 7;
[0110]
[0111] x i ~x 2 (2J),(5)
[0112] CP i =CDF(x i ), (6)
[0113]
[0114] in, represents the P value of the i-th gene after transformation on the j-th predictor, where J is the number of predictors, and x i represents the combined statistic of the ith gene, χ 2(2J) represents the combined statistic X with 2J degrees of freedom 2 The distribution of CP i represents the combined P value of the ith gene, i.e., the eCDF of the chi-square distribution at x i The value of CS i represents the finite fraction of the i-th gene, a total of K genes, CP k represents the combined P value of the kth gene.
[0115] (6) Pathway intersection network analysis to identify key targets: Based on the prioritized genes, a pathway intersection network analysis is constructed to identify key targets, specifically:
[0116] Based on the above-identified priority genes, it is necessary to explore the gene interaction network relationship. For this purpose, the present invention maps them to the KEGG pathway information to explore their relationship. The top-ranked priority genes are selected, and a gene subset with a high priority and a high degree of correlation is identified in the KEGG network using the heuristic Stein tree search algorithm. It is necessary to ensure that the interaction relationship between each gene or the edge in the KEGG network exists in at least one pathway. The gene subnetwork composed of the identified gene subset is the pathway intersection network. In order to evaluate the significance of the pathway intersection network, a 100-iteration degree-preserving node permutation test is selected for evaluation. The key targets finally output are all the nodes gathered on the pathway intersection network after iterative search.
[0117] The identified pathway intersections can be represented not only as gene networks, but also at the pathway level, where pathways are nodes and edges represent the inferred associations between pathways. Pathways that are significantly enriched for intersectional genes are identified as nodes only if they pass the lateral Fisher's exact test. The edges in the network are first inferred based on the member genes shared between pathways, and then filtered by identifying the minimum spanning tree using the igraph package (version 1.3.5). This process only retains the edges present in the spanning tree, and the thickness of the edges is adjusted proportionally according to the number of shared member genes between the two endpoint pathways.
[0118] (7) Identifying evidence of drug reuse based on pathway intersection networks: Identifying evidence of drug reuse based on the pathway intersection networks, specifically:
[0119] Drug repurposing analysis relies on information extracted from the bioactive compound database ChEMBL, which summarizes therapeutic data including drugs, development stages, target genes, and disease indications for current phase II and approved therapies;
[0120] For the chronic complex disease to be predicted, considering that the key target gene has a clear mechanism of action and can explain the efficacy of the drug in treating the disease, the drug that has reached the maximum stage of development will be selected by the key target gene;
[0121] The genes of these selected key targets were divided into two different groups: one group included approved drug targets (i.e., genes targeted by any approved drug), and the other group included drug targets under development (i.e., genes targeted by unapproved drugs in development, not any approved drugs). The one-sided Fisher's exact test was used to evaluate the statistical significance of the two groups of drug targets (i.e., approved drug targets and drug targets under development) enriched in pathway intersection genes.
[0122] S2: Based on the key targets and the drug reuse evidence, a TCMnet database network related to traditional Chinese medicine is constructed, and based on the key targets, predictions are made on traditional Chinese medicine compound prescriptions, traditional Chinese medicine compounds, disease treatment plans and disease health care plans.
[0123] In this embodiment, step S2 is the process of drug target prediction based on TCM data: based on the prediction of chronic disease treatment targets identified by the prioritized genes supported by genomics data and TCM-related database information, the targets at the gene level are converted into information related to TCM ingredients and TCM targets. Subsequently, based on this information, a "drug-target-disease-symptom" network is constructed for each TCM ingredient, and finally potential TCM targets and related TCM compound information are identified.
[0124] (1) Constructing a TCM-related database network TCMnet: Based on the key targets and the drug repurposing evidence, construct a TCM-related database network, specifically:
[0125] Retrieve information from TCM-related databases, including the TCMSP database and analysis platform for TCM systems pharmacology, SymMap database for TCM syndrome association, and BATMAN-TCM2.0 database for TCM pharmacology, and manually organize the information, focusing on the relationship between drugs, targets, diseases, and symptoms;
[0126] Based on the TCM-related database information, the information on Chinese herbal medicine types, Chinese herbal medicine ingredients, Chinese herbal medicine compounds, TCM symptoms, modern medical symptoms, disease information, and gene target points are sorted out and finally summarized into the TCM-related database network associated with "drug-target-disease-symptom", which is initially named TCMnet. The relevant data is stored in the form of a MySQL database. The TCM-related database network supports gene target searches for Chinese herbal medicine ingredients, or searches for gene targets based on Chinese herbal medicine ingredients, or searches for gene targets and Chinese herbal medicine ingredients through diseases.
[0127] The present invention also provides expandable functions, such as the ability to annotate the ingredients of Chinese herbal medicine compounds with additional information, including the ability to provide evaluation data on human absorption, distribution, and metabolic properties for each compound, and information such as oral bioavailability, drug similarity, intestinal epithelial permeability, blood-brain barrier, water solubility, and other pharmacokinetic characteristics of natural compounds.
[0128] (2) Prediction of Chinese medicine compound based on candidate targets, specifically:
[0129] Based on the genes of the key targets identified by the pathway intersection network, the Chinese medicine related database network TCMnet is used to retrieve the Chinese herbal medicine types related to the genes of the key targets, and the frequency statistical analysis of the Chinese herbal medicine types included in the group is performed, and the Chinese herbal medicine components that appear more than half of the times in the genes of the key targets are selected as the recommended Chinese medicine treatment compound;
[0130] In order to ensure the effectiveness of the recommended TCM compound, the core formulas for diseases currently published were searched in the literature for further comparison, and finally the TCM compound for complex diseases was determined.
[0131] (3) Prediction of Chinese medicine compounds based on candidate targets, specifically:
[0132] Based on the genes of the key targets identified by the pathway intersection network, the TCMnet related database network is used to search for the gene-related Chinese herbal compounds of the key targets, and the included Chinese herbal compound components are searched. The Chinese herbal compound components that appear more than half of the times in the genes of the key targets are selected, and the corresponding additional information annotations are retrieved at the same time. According to the top-ranked Chinese herbal compound component table, the corresponding combination is selected for subsequent research.
[0133] (4) Prediction of disease treatment options based on candidate targets, specifically:
[0134] Based on the genes of the key targets identified by the pathway intersection network, the corresponding disease type is selected, and the Chinese herbal medicine types and compounds related to the genes of the key targets are retrieved using the Chinese medicine-related database network. The pathway intersection network analysis is constructed for the Chinese herbal medicine types and compound components included in the group to identify the key Chinese herbal medicine types and compound components. At the same time, relevant Chinese herbal medicine types can be added by customization, and finally candidate disease treatment plans are output.
[0135] (5) Prediction of disease and health care solutions based on candidate targets, specifically:
[0136] Based on the genes of the key targets identified by the pathway intersection network, the relevant disease types are selected, and the Chinese herbal medicine types and compounds related to the genes of the key targets are retrieved using the Chinese medicine-related database network. The pathway intersection network analysis is constructed for the Chinese herbal medicine types and compound components included in the group to identify the key Chinese herbal medicine types and compound components. At the same time, relevant Chinese herbal medicine types can be added by customization, and finally the disease health care plan that can be recommended by the present invention is output.
[0137] The present invention can also provide users with a multi-faceted consultation system, which is convenient for users to more intuitively understand the disease type corresponding to the symptoms and how to select symptom information, so that users can more accurately screen out corresponding disease treatment plans and disease health care plans.
[0138] Second embodiment
[0139] like Figure 2 As shown, this embodiment provides a genetically driven Chinese medicine target prediction and evaluation system for executing the genetically driven Chinese medicine target prediction and evaluation method as in the first embodiment, comprising:
[0140] The key gene prediction module 1 is used to obtain the significant associated SNP sites of the chronic complex disease to be predicted as the whole genome association study data, identify the key genes and key associated genes regulated by the significant associated SNP sites, construct a gene-prediction factor matrix based on the significant associated SNP sites, the key genes and the key associated genes, identify the priority genes based on the gene-prediction factor matrix, construct a pathway intersection network analysis based on the priority genes to identify the key targets, and identify the drug reuse evidence based on the pathway intersection network;
[0141] The drug target prediction module 2 is used to construct a traditional Chinese medicine related database network TCMnet based on the key targets and the drug reuse evidence, and to predict traditional Chinese medicine compound prescriptions, traditional Chinese medicine compounds, disease treatment plans and disease health care plans based on the key targets.
[0142] Third embodiment
[0143] This example proposes a genetically driven method for predicting TCM targets, including two steps: prioritizing gene prediction based on genomics data and drug target prediction based on TCM data. The specific principle is as follows: Figure 3 shown.
[0144] The following uses autoimmune thyroid disease as an example to illustrate the practicability of the present method: The present invention is further illustrated by using specific examples:
[0145] (1) Performance benchmark (comparison with existing methods):
[0146] Prioritized gene prediction based on genomics data can effectively transform genetic methods for complex diseases into predictions of TCM targets supported by genetic evidence. The present invention uses GWAS summary data of autoimmune diseases to systematically evaluate the performance of TCM target prediction for complex diseases. By selecting different combinations of predictors to benchmark the performance of the prioritization method, the present invention compares three similar meta-analysis methods (Logistic, Fisher's, orderstatistic) and two traditional analysis methods (sum, max). The results show that the meta-analysis-like scheme, especially the Logistic scheme, performs significantly better than the traditional scheme ( Figure 4 a). At the same time, it is compared with existing methods, including downloading drug targets for autoimmune thyroid diseases from the Open Targets database and obtaining drug targets with clinical concept support from the ChEMBL database ( Method), further performance benchmarking was performed and it was found that the Logistic method performed best, had higher sensitivity, and had higher accuracy ( Figure 4 b).
[0147] (2) Prioritization approach Autoimmune thyroid disease
[0148] Using the summary data of all GWAS of autoimmune thyroid diseases, limited ranking analysis was used to prioritize genetic targets, and about 14,700 prioritized genes were predicted. For each gene, a priority rating (score 0-10; Figure 5 a). Subsequently, the generated priority genes were subjected to disease enrichment analysis to reveal the molecular pathways of autoimmune diseases and improve the research progress of current treatment methods for autoimmune diseases. We performed disease enrichment analysis on the top 5% of the priority genes and found that 19 genes were clinical concept proof target genes for autoimmune diseases (clinical phase II or above drug targets). Most of these targets (17 / 19) have been approved as drug targets for other disease indications, including FKBP1A, VDR, PGR, NR3C1, CD40, IL6R, IL17A, CD3E, THRA, and THRB. At the same time, we performed KEGG pathway enrichment analysis on the top 5% of the priority genes and found that these target genes are closely related to immune response and cell signaling. Among them, THRA and THRB are protein-coding genes for thyroid hormone receptors ( Figure 5 bc).
[0149] (3) Application of the prioritization method to quantitatively recommend gene ranking for different subtypes of autoimmune thyroid disease
[0150] The discovery of subtype-specific drug targets will provide better treatment for patients with autoimmune thyroid disease. Therefore, we next applied the prioritization method to the GWAS summary data of two different clinical manifestations of autoimmune thyroid disease subtypes, namely hyperthyroidism and hypothyroidism. We prioritized the target genes (and the molecular features they are involved in) for each subtype. A Manhattan plot was used to display all the prioritized target genes in the genome ( Figure 6 The present invention uses 50 supergene sets from the MSigDB database to identify the common features of the top 1% of genes ( Figure 7 ). The study found that both hyperthyroidism and hypothyroidism were associated with most immune-related features (TNF-α signaling pathway and PI3K / AKT / mTOR signaling pathway), and were also associated with cell apoptosis. It is worth noting that features related to angiogenesis and interferon γ response were only enriched in hyperthyroidism, while hypothyroidism was enriched in pathways related to inflammatory response and cell death. The above results suggest that hyperthyroidism may be highly correlated with T cell-driven adaptive immunity, while hypothyroidism is highly correlated with innate immune response.
[0151] (4) Pathway intersection network analysis to identify key genes
[0152] Based on the quantitatively recommended priority genes identified above, we also integrated them with KEGG pathway-derived information to further analyze the gene-gene interaction network relationship and ultimately determine a high-priority gene network that mediates the intersection of molecular pathways. The results showed that a pathway intersection network involving 55 genes was identified in hyperthyroidism (P-value = 6.72×10 -97 ), a pathway intersection network involving 51 genes was identified in hypothyroidism (P-value = 2.29 × 10 -105 A total of 33 shared key genes (>50%), 22 hyperthyroidism-specific genes and 18 hypothyroidism-specific genes were found in the two pathway intersection networks (i.e., shared by hyperthyroidism and hypothyroidism). Figure 8 ). We analyzed the pathway distribution of these three types of key genes and found that most of the shared key genes were enriched in the ERBB (immune-related) and growth factor-related signaling pathways, while the key genes specific to hypothyroidism were specifically enriched in the PI3K / AKT / mTOR signaling pathway and the RAS signaling pathway.
[0153] (5) Evidence of drug repurposing based on pathway intersection networks
[0154] Looking beyond autoimmune thyroid disease, we found that shared, overlapping key target genes were most supported by clinical proof of concept (drugs in development) and clinical evidence (approved drugs) ( Fig. 9a). Specifically, the key target genes of the shared intersections have highly supported clinical evidence (approved drugs), and 6 drug target genes that have been approved for other diseases were identified. Hyperthyroidism (5) and hypothyroidism (5) specific intersection genes have approved targeted drugs for other disease indications ( Fig. 9 b).
[0155] (6) Identify the components of TCM compound prescriptions corresponding to potential targets based on TCM database
[0156] According to the shared and specific pathway intersection key target genes, the TCMnet database related to traditional Chinese medicine described in the present invention was used to retrieve the Chinese medicine ingredients corresponding to the key target genes. We performed frequency statistical analysis on the Chinese medicine ingredients of each group of target genes, selected the Chinese medicine ingredients with a frequency of more than half in each group, and then compared them with the core formula of Beijing University of Chinese Medicine for the treatment of hyperthyroidism (9 Chinese medicines: Bupleurum, Rehmannia glutinosa, White Peony Root, Prunella Vulgaris, Poria, Cornus officinalis, Atractylodes macrocephala, Paeonia suffruticosa, Astragalus) and the core formula of hypothyroidism (8 Chinese medicines: Perilla leaf, White Peony Root, Poria, Magnolia Bark, Bupleurum, Tangerine Peel, Raw Astragalus, French Pinellia). The results showed that 24 Chinese medicine ingredients were found in the shared intersection genome (n=33), and included the same Smilax glabra, Tangerine Peel, Astragalus, White Peony Root, and Paeonia suffruticosa as the core formula, which also shows that the composition of these Chinese medicines can be used for the treatment of autoimmune thyroid diseases. In the hypothyroidism-specific group (n=22), there were 7 Chinese herbal ingredients, including Smilax glabra and Perilla leaf compared with the core formula of hypothyroidism. Similarly, there were 13 Chinese herbal ingredients in the hyperthyroidism-specific group (n=18), including Astragalus, Smilax glabra and Cornus officinalis. Fig.10 ). This suggests that the TCM targets and TCM compound prescriptions identified by the present invention with genetic evidence drive have strong feasibility and can provide new directions for subsequent research.
[0157] A computer-readable storage medium stores a computer code. When the computer code is executed, the above method is executed. A person skilled in the art can understand that all or part of the steps in the various methods of the above embodiments can be completed by instructing related hardware through a program. The program can be stored in a computer-readable storage medium. The storage medium can include: a read-only memory (ROM), a random access memory (RAM), a disk or an optical disk, etc.
[0158] The above is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments. All technical solutions under the concept of the present invention belong to the protection scope of the present invention. It should be pointed out that for ordinary technicians in this technical field, some improvements and modifications without departing from the principle of the present invention should also be regarded as the protection scope of the present invention.
[0159] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0160] It should be noted that the above embodiments can be freely combined as needed. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered as the protection scope of the present invention.
Claims
1. A genetically driven method for predicting and evaluating traditional Chinese medicine targets, characterized in that: The following steps are involved: S1: Obtain the significant associated SNP sites of the chronic complex diseases to be predicted as genome-wide association study data, identify the key genes and key associated genes regulated by the significant associated SNP sites, construct a gene-predictor matrix based on the significant associated SNP sites, the key genes and the key associated genes, identify priority genes based on the gene-predictor matrix, construct a pathway intersection network analysis based on the priority genes to identify key targets, and identify drug repurposing evidence based on the pathway intersection network; S2: Based on the key targets and the drug reuse evidence, a TCMnet database network related to traditional Chinese medicine is constructed, and based on the key targets, predictions are made on traditional Chinese medicine compound prescriptions, traditional Chinese medicine compounds, disease treatment plans and disease health care plans.
2. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 1, characterized in that: In step S1, the key gene regulated by the significant associated SNP site and the key associated gene are identified, specifically: In order to identify the key gene regulated by the significant associated SNP site of the genetic locus to be predicted for the chronic complex disease, multimodal regulatory genomics data is used to define, including at least one of the following: A: Neighbor factor associated with the significant associated SNP site; B: defining genetic regulatory factors according to the expression quantitative trait loci eQTL or protein quantitative trait loci pQTL associated with the chronic complex disease to be predicted; C: Definition of long-range interacting factors based on promoter capture Hi-C data; Taking the key gene as the initial starting point, by integrating the protein interaction network data, the random walk algorithm RWR with restart is used to calculate the degree of connection between the protein interaction network data and the key gene, and then identify the key associated gene of the key gene, specifically: Referring to Formula 1, starting with the key gene as a node, there are two choices at each walk: either move to a randomly selected neighboring node, or jump back to the starting point, and iterate repeatedly until all nodes are traversed. Referring to Formula 2, the probability vector obtained at this time contains all nodes, that is, the affinity scores of all key associated genes with the key gene as the initial starting point, ranging from 0 to 1; Wherein, γ represents the restart probability of jumping back to the seed node, the seed node is the initial starting point, 1-γ represents the probability of moving to the neighboring node, A represents the standardized Laplacian adjacency matrix related to the network data, represents the starting probability vector containing the seed gene scores, which is 0 for non-seed genes. represents the probability vector of the stable state of the algorithm when visiting the network node for the tth time, The probability vector representing the stable state of the algorithm visiting the network node for the t-1th time, after reaching stability, assigning the affinity scores of all nodes in the network to the seed node.
3. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 2, characterized in that: In step S1, the gene-prediction factor matrix is constructed based on the significant associated SNP sites, the key genes and the key associated genes, specifically: The neighbor factor, the genetic regulatory factor and the long-range interaction factor are used as predictors, the neighbor factor is used as a baseline predictor, and a subset having the same weight as the neighbor factor is obtained from the genetic regulatory factor and the long-range interaction factor; Mapping all the predictors to genes, constructing the gene-predictor matrix, wherein the X-axis represents the gene, the Y-axis represents the predictor, and each element in the gene-predictor matrix represents the strength of association between a gene and a predictor; Considering genes and the predictors as nodes in a graph, and considering the associations between genes and the predictors as edges, a network graph is constructed; A random walk algorithm is used to walk on the constructed network graph to calculate the weight of each prediction factor. After removing a certain prediction factor, the walk is performed again to measure the change in the weight of the prediction factor. If the accuracy drops significantly after removing a certain prediction factor, the prediction factor is considered to be valuable and is retained.
4. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 3, characterized in that: In step S1, the priority genes are identified based on the gene-prediction factor matrix, specifically: Prioritization prediction is performed using a logistic scheme similar to a meta-analysis method, and predictor variables are merged according to the constructed gene-predictor matrix, in which the affinity score of the predictor given by formula 3 is converted into a P-value by an empirical cumulative density function eCDF, and the empirical cumulative density function eCDF is estimated by the affinity scores of all genes on the predictor; in, represents the affinity score of the ith gene on the jth predictor, represents the P value of the i-th gene after conversion on the j-th predictor; Subsequently, referring to formulas 4-6, the transformed P values of different predictors are combined by the Logistic scheme, and the final combined P value is readjusted to produce a priority level from 0 to 10, and the output result is the priority ranking method of the priority ranking genes, referring to formula 7; x i ~χ 2 (2J), (5) CP i =CDF(x i ), (6) in, represents the P value of the i-th gene after transformation on the j-th predictor, where J is the number of predictors, and x i represents the combined statistic of the ith gene, χ 2 (2J) represents the combined statistic χ with 2J degrees of freedom 2 The distribution of CP i represents the combined P value of the ith gene, i.e., the eCDF of the chi-square distribution at x i The value of CS i represents the finite fraction of the i-th gene, a total of K genes, CP k represents the combined P value of the kth gene.
5. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 4, characterized in that: In step S1, a pathway intersection network analysis is constructed based on the prioritized genes to identify key targets, specifically: The top-ranked priority genes are selected, and a high-priority and highly correlated gene subset is identified in the KEGG network using a heuristic Stein tree search algorithm. It is also necessary to ensure that the interaction relationship between each gene or the edge in the KEGG network exists in at least one pathway. The gene subnetwork composed of the identified gene subset is the pathway intersection network. In order to evaluate the significance of the pathway intersection network, a 100-iteration degree-preserving node permutation test is selected for evaluation. The key targets finally outputted are all the nodes gathered on the pathway intersection network after iterative search.
6. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 5, characterized in that: In step S1, drug repurposing evidence is identified based on the pathway intersection network, specifically: Drug repurposing analysis relies on information extracted from the bioactive compound database ChEMBL, which summarizes therapeutic data including drugs, development stages, target genes, and disease indications for current phase II and approved therapies; For the chronic complex disease to be predicted, considering that the key target gene has a clear mechanism of action and can explain the efficacy of the drug in treating the disease, the drug that has reached the maximum stage of development will be selected by the key target gene; The genes of these selected key targets were divided into two different groups: one group included approved drug targets and the other group included drug targets under development, and the one-sided Fisher's exact test was used to assess the statistical significance of the enrichment of the two groups of drug targets into pathway intersection genes.
7. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 1, characterized in that: In step S2, based on the key targets and the drug reuse evidence, a TCMnet database network is constructed, specifically: Retrieve information from TCM-related databases, including the TCMSP database and analysis platform for TCM systems pharmacology, SymMap database for TCM syndrome association, and BATMAN-TCM2.0 database for TCM pharmacology, and manually organize the information, focusing on the relationship between drugs, targets, diseases, and symptoms; Based on the TCM-related database information, the information on Chinese herbal medicine types, Chinese herbal medicine ingredients, Chinese herbal medicine compounds, TCM symptoms, modern medical symptoms, disease information, and gene target points are sorted out and finally summarized into the TCM-related database network TCMnet associated with drugs, targets, diseases, and symptoms. The relevant data is stored in the form of a MySQL database. The TCM-related database network supports searching for Chinese herbal medicine ingredients by gene targets, or searching for gene targets based on Chinese herbal medicine ingredients, or searching for gene targets and Chinese herbal medicine ingredients by diseases.
8. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 7, characterized in that: In step S2, the Chinese medicine compound is predicted based on the key targets, specifically: Based on the genes of the key targets identified by the pathway intersection network, the Chinese medicine-related database network is used to retrieve the Chinese herbal medicine types related to the genes of the key targets, and the frequency statistical analysis of the Chinese herbal medicine types included in the group is performed, and the Chinese herbal medicine components that appear more than half of the times in the genes of the key targets are selected as the recommended Chinese medicine treatment compound; In order to ensure the effectiveness of the recommended TCM compound, the core formulas for diseases currently published were searched in the literature for further comparison, and finally the TCM compound for complex diseases was determined.
9. The genetically driven traditional Chinese medicine target prediction and evaluation method according to claim 7, characterized in that: In step S2, the Chinese medicine compound is predicted based on the key target, specifically: Based on the genes of the key targets identified by the pathway intersection network, the Chinese medicine-related database network is used to retrieve the Chinese herbal compounds related to the genes of the key targets, and the included Chinese herbal compound components are searched, and the Chinese herbal compound components that appear more than half of the times in the genes of the key targets are selected. At the same time, the corresponding additional information annotations are retrieved, and the corresponding combination is selected for subsequent research based on the top-ranked Chinese herbal compound component table.
10. A genetically driven Chinese medicine target prediction and evaluation system for executing the genetically driven Chinese medicine target prediction and evaluation method as claimed in any one of claims 1 to 9, characterized in that: include: A key gene prediction module is used to obtain the significant associated SNP sites of the chronic complex disease to be predicted as genome-wide association study data, identify the key genes and key associated genes regulated by the significant associated SNP sites, construct a gene-prediction factor matrix based on the significant associated SNP sites, the key genes and the key associated genes, identify priority genes based on the gene-prediction factor matrix, construct a pathway intersection network analysis based on the priority genes to identify key targets, and identify drug repurposing evidence based on the pathway intersection network; The drug target prediction module is used to construct a traditional Chinese medicine related database network TCMnet based on the key targets and the drug reuse evidence, and to predict traditional Chinese medicine compound prescriptions, traditional Chinese medicine compounds, disease treatment plans and disease health care plans based on the key targets.
Citation Information
Cited By
Drug structure-activity relationship analysis method and device based on multi-level structure
CN120280031A
Cancer suppression target gene prediction method driven by cloned hematopoietic multi-phenotype genetic big data, electronic equipment and program product
CN120564843A
Disease target discovery method and system driven by multi-omics data and computer storage medium
CN121122414A
